Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Citius Pharmaceuticals stock | $2.03

Learn how to easily invest in Citius Pharmaceuticals stock.

Citius Pharmaceuticals Inc is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Citius Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTXR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Citius Pharmaceuticals stock price (NASDAQ: CTXR)

Use our graph to track the performance of CTXR stocks over time.

Citius Pharmaceuticals shares at a glance

Information last updated 2021-10-16.
Latest market close$2.03
52-week range$0.87 - $4.56
50-day moving average $2.08
200-day moving average $2.19
Wall St. target price$7.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.28

Buy Citius Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Citius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Citius Pharmaceuticals price performance over time

Historical closes compared with the close of $2.03 from 2021-10-21

1 week (2021-10-13) -0.49%
1 month (2021-09-22) -4.69%
3 months (2021-07-22) 1.50%
6 months (2021-04-22) 12.78%
1 year (2020-10-22) 84.55%
2 years (2019-10-22) 244.42%
3 years (2018-10-22) 26.09%
5 years (2016-10-21) 223.76%

Citius Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -15.18%
Return on equity TTM -26.76%
Profit margin 0%
Book value $0.94
Market capitalisation $305.1 million

TTM: trailing 12 months

Shorting Citius Pharmaceuticals shares

There are currently 14.5 million Citius Pharmaceuticals shares held short by investors – that's known as Citius Pharmaceuticals's "short interest". This figure is 0.3% up from 14.4 million last month.

There are a few different ways that this level of interest in shorting Citius Pharmaceuticals shares can be evaluated.

Citius Pharmaceuticals's "short interest ratio" (SIR)

Citius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Citius Pharmaceuticals shares currently shorted divided by the average quantity of Citius Pharmaceuticals shares traded daily (recently around 2.9 million). Citius Pharmaceuticals's SIR currently stands at 4.96. In other words for every 100,000 Citius Pharmaceuticals shares traded daily on the market, roughly 4960 shares are currently held short.

However Citius Pharmaceuticals's short interest can also be evaluated against the total number of Citius Pharmaceuticals shares, or, against the total number of tradable Citius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Citius Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Citius Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1082% of the tradable shares (for every 100,000 tradable Citius Pharmaceuticals shares, roughly 108 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Citius Pharmaceuticals.

Find out more about how you can short Citius Pharmaceuticals stock.

Citius Pharmaceuticals share dividends

We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.

Have Citius Pharmaceuticals's shares ever split?

Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.

Citius Pharmaceuticals share price volatility

Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.873 up to $4.56. A popular way to gauge a stock's volatility is its "beta".

CTXR.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.5407. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Citius Pharmaceuticals overview

Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .

Frequently asked questions

What percentage of Citius Pharmaceuticals is owned by insiders or institutions?
Currently 8.431% of Citius Pharmaceuticals shares are held by insiders and 21.917% by institutions.
How many people work for Citius Pharmaceuticals?
Latest data suggests 10 work at Citius Pharmaceuticals.
When does the fiscal year end for Citius Pharmaceuticals?
Citius Pharmaceuticals's fiscal year ends in September.
Where is Citius Pharmaceuticals based?
Citius Pharmaceuticals's address is: 11 Commerce Drive, Cranford, NJ, United States, 07016
What is Citius Pharmaceuticals's ISIN number?
Citius Pharmaceuticals's international securities identification number is: US17322U2078
What is Citius Pharmaceuticals's CUSIP number?
Citius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 17322U207

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site